TriSalus Life Sciences (TLSI) announces the appointment of David Patience as Chief Financial Officer, effective July 1, 2025. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Young remains available to the Company to support an orderly transition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- Trisalus Life Sciences Q1 2025 Earnings Call Highlights
- TriSalus Life Sciences: Strategic Developments and Revenue Growth Drive Buy Rating
- TriSalus Life Sciences management to meet virtually with Lake Street
- TriSalus Life Sciences: Strong Financial Performance and Strategic Focus Drive Buy Rating
- TriSalus Life Sciences: Promising Growth Trajectory and Strategic Focus Justify Buy Rating